Mode
Text Size
Log in / Sign up

Multicomponent nonpharmacological interventions reduce delirium incidence in adult patients with cancerNon-drug approaches cut delirium risk in cancer patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider multicomponent nonpharmacological interventions to reduce delirium risk in postoperative cancer patients.

The researchers evaluated the efficacy of nonpharmacological interventions, including multicomponent strategies, bright light therapy, rehabilitation, and anesthesia or oxygen management, in reducing delirium among adult patients with cancer. The analysis focused on identifying which specific approaches yielded consistent results for preventing cognitive impairment.

The findings indicated that multicomponent interventions were associated with a significant reduction in delirium incidence, especially within postoperative environments. In contrast, the evidence regarding bright light therapy as a standalone intervention was reported as inconclusive. The authors noted moderate certainty for multicomponent strategies but very low certainty for other specific nonpharmacological methods.

Several limitations were identified, including potential risks of bias due to lack of blinding and significant heterogeneity across patient populations and healthcare settings. Furthermore, the evidence supporting standalone interventions or prevention strategies in palliative or end-of-life care remains limited. Clinicians may consider multicomponent approaches for postoperative patients while noting the current lack of robust data for other specific nonpharmacological modalities.

Delirium is a sudden, serious confusion that can hit cancer patients, especially after surgery. It's scary for patients and families, and it can lead to longer hospital stays and worse outcomes. But a new analysis of 24 studies involving 2,747 patients offers some hope: certain non-drug approaches may help prevent it.

The review found that multicomponent interventions, which combine several strategies like reorientation, sleep hygiene, and early mobility, significantly reduced delirium risk. The effect was strongest in postoperative settings. The risk was cut by more than half (RR 0.43). The evidence for this approach is moderate, meaning it's fairly reliable.

Other standalone interventions, like bright light therapy, showed promise but the evidence was too weak to draw firm conclusions. The review also noted limitations: many studies had bias risks because patients and staff knew who was getting the intervention, and the types of patients and treatments varied widely. For patients in palliative or end-of-life care, the evidence remains limited.

Overall, this suggests that hospitals should consider using multicomponent non-drug programs to protect cancer patients from delirium, especially around the time of surgery. But more research is needed to know what works best in different situations.

What this means for you:
Combining non-drug strategies like reorientation and sleep help can lower delirium risk in cancer patients after surgery.

Common questions

What is delirium in cancer patients?

Delirium is a sudden state of confusion, agitation, or drowsiness that can happen in people with cancer, especially after surgery or during advanced illness. It can be frightening and may lead to longer hospital stays or complications.

What non-drug interventions help prevent delirium?

The review found that multicomponent interventions, which combine several strategies like reorientation (reminding patients where they are), promoting sleep, and early mobility, significantly reduced delirium. Bright light therapy showed promise but the evidence was not strong enough to confirm benefit.

Are there any side effects of these non-drug interventions?

The review did not report any side effects or safety concerns for the non-drug interventions studied. However, the quality of the evidence was limited by lack of blinding, so some benefits may be overestimated.

Study Details

Study typeMeta analysis
Sample sizen = 2,747
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
PURPOSE: To determine whether nonpharmacological interventions reduce delirium incidence in adult patients with cancer and to identify effective intervention strategies. METHOD: We conducted a systematic review and meta-analysis following PRISMA guidelines. PubMed, CENTRAL, CINAHL, and Ichushi-Web were searched through September 30, 2024, for randomized controlled trials (RCTs). Two authors independently extracted data, assessed the risk of bias using the Cochrane Risk of Bias 2 tool, and evaluated the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. The primary outcome was delirium incidence. A random-effects model was used for the meta-analysis. The study protocol was registered with UMIN-CTR (No. UMIN000051804; registered August 2, 2023). RESULTS: Overall, 12 RCTs involving 2,747 patients were included. Interventions were categorized into multicomponent interventions, bright light therapy, rehabilitation, and anesthesia or oxygen management. The meta-analysis of five trials showed that multicomponent interventions significantly reduced delirium incidence (risk ratio [RR], 0.43; 95% confidence interval [CI], 0.31-0.60; moderate-certainty evidence), with benefit predominantly observed in postoperative settings. The evidence for bright light therapy was inconclusive (RR, 0.31; 95%CI, 0.07-1.31; very low-certainty evidence). Most of the included studies had concerns regarding the risk of bias, mainly due to a lack of blinding. CONCLUSION: Multicomponent nonpharmacological interventions may reduce delirium incidence in adult patients with cancer, particularly in postoperative or perioperative settings. However, the certainty of evidence is moderate, and the included studies vary in patient populations, intervention components, and healthcare settings. Evidence for standalone interventions and prevention strategies in palliative or end-of-life care remains limited and inconclusive.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.